GlycoMimetics Unternehmenskultur

Mr. Brian M. Hahn has been the Chief Financial Officer of GlycoMimetics, Inc. since January 5, 2012 and serves as its Secretary. Mr. Hahn joined GlycoMimetics in 2010. He served as an Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical). Prior to Advancis, he was a Senior Accountant with Bering Truck Corporation. He began his career as an auditor for the Bank of Clarke County. Over the last ten years, he has worked with life science companies from early stages (including an initial public offering) through product launch. He has over 15 years of senior financial and operations experience in emerging organizations. He has broad experience in developing strategic plans, creating business models, establishing accounting and auditing systems and ensuring Sarbanes-Oxley compliance. He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.

Dr. John L. Magnani, Ph.D. has been Chief Scientific Officer of Glycomimetics, Inc. since 2003 and its Senior Vice President since January 9, 2017. Dr. Magnani served as Vice President of Research at Glycomimetics, Inc. since 2003 until January 9, 2017. Dr. Magnani served as Vice President at Glycomimetics, Inc. since August 22, 2015. Dr. Magnani served as Secretary at Glycomimetics, Inc. Dr. Magnani remained at the NIH for ten years, finally serving as a tenured Research Chemist. He left the NIH in 1988 and helped Co-found the U.S. subsidiary of BioCarb and became its Vice President of Research. In 1992, he founded and managed GlycoTech Corp. as its President and Chief Executive Officer. He is the discoverer of Sialyl Lewisa and its functions. He was the first to identify the binding domain to the selectins common to both Sialyl Lewisa and Sialyl Lewisx and used this information to develop potent selectin inhibitors. During his career, he also identified and characterized many carbohydrate tumor antigens and developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani has been Director at GlycoMimetics, Inc Since 2003. Dr. Magnani received Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health.

Dr. Helen M. Thackray, M.D., FAAP, has been Chief Medical Officer and Senior Vice President of Clinical Development at GlycoMimetics, Inc. since January 2012 and January 9, 2017 respectively. Dr. Thackray served as Vice President of Clinical Development at GlycoMimetics, Inc. since 2006 until January 9, 2017. She served as Vice President of Clinical Product Development of Biosynexus Inc. from 2001 to 2006. Dr. Thackray was responsible for managing all aspects of clinical development. She holds appointment as Assistant Clinical Professor of Pediatrics at the George Washington University School of Medicine. Her background in pharmaceutical science includes experience with major academic and industry institutions in both biochemical and preclinical infectious disease research. She is a member of the Institutional Review Board of the National Center for Healthcare Statistics and is a Fellow of the American Academy of Pediatrics. She earned a B.S. from Stanford University and an M.D. from George Washington University School of Medicine. She completed a Pediatrics residency at Children's National Medical Center in Washington, D.C., where she served as Pediatric Chief Resident and Adjunct Instructor in Pediatrics. Dr. Thackray also studied at the National Human Genome Research Institute of the National Institutes of Health as a Medical Genetics Fellow.

Armand Girard serves as the Vice President Corporate Development of GlycoMimetics. Armand started at GlycoMimetics in Mar of 2014. Armand currently resides in the Washington D.C. Metro Area.

Brian Hahn serves as the Chief Financial Officer of GlycoMimetics. Brian started at GlycoMimetics in Feb of 2010. Brian currently resides in the Washington D.C. Metro Area.

Pat Andrews serves as the Member Board Of Directors of GlycoMimetics. Pat started at GlycoMimetics in June of 2017. Pat currently resides in the Greater Boston Area.